ID
44154
Beschreibung
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln
Stichworte
Versionen (5)
- 26.12.17 26.12.17 -
- 27.12.17 27.12.17 -
- 15.03.21 15.03.21 - Dr. rer. medic Philipp Neuhaus
- 13.04.21 13.04.21 - Dr. rer. medic Philipp Neuhaus
- 20.09.21 20.09.21 -
Rechteinhaber
Universität zu Köln
Hochgeladen am
20. September 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314
Study relevant visits
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
Beschreibung
Beurteilung der Lebensqualität
Beschreibung
Surrogatmarker
Beschreibung
undefined item
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0079611
Beschreibung
Collection of blood specimen for laboratory procedure Date in time
Datentyp
date
Maßeinheiten
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0178913
- UMLS CUI [1,2]
- C0011008
Beschreibung
Report sent?
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1524049
- UMLS CUI [1,2]
- C0520510
- UMLS CUI [1,3]
- C0008976
- UMLS CUI [1,4]
- C0205099
Beschreibung
biomarker
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0005516
Beschreibung
Date blood sample
Datentyp
date
Maßeinheiten
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0005834
- UMLS CUI [1,2]
- C0011008
Beschreibung
Specimen sent
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1524049
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0205099
Beschreibung
Batch
Datentyp
boolean
Alias
- UMLS CUI [1]
- C3641829
Beschreibung
Shipping date in time
Datentyp
date
Maßeinheiten
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0370003
- UMLS CUI [1,2]
- C1524049
- UMLS CUI [1,3]
- C0011008
Beschreibung
Bemerkung
Ähnliche Modelle
Study relevant visits
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
C0392360 (UMLS CUI [1,2])
C0034380 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0520510 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205099 (UMLS CUI [1,4])
C0011008 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
C0205099 (UMLS CUI [1,3])
C1524049 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])